Savara Inc (NASDAQ:SVRA) Receives Average Rating of "Buy" from Brokerages

Shares of Savara Inc (NASDAQ:SVRA - Get Free Report) have received a consensus rating of "Buy" from the six analysts that are covering the firm, MarketBeat reports. Six investment analysts have rated the stock with a buy recommendation. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $11.17.

SVRA has been the subject of several research analyst reports. HC Wainwright reiterated a "buy" rating and issued a $10.00 price objective on shares of Savara in a research note on Tuesday, October 8th. Oppenheimer lifted their price target on shares of Savara from $11.00 to $15.00 and gave the company an "outperform" rating in a research note on Wednesday, June 26th. Guggenheim increased their price objective on shares of Savara from $8.00 to $10.00 and gave the stock a "buy" rating in a research report on Thursday, June 27th. Finally, JMP Securities reaffirmed a "market outperform" rating and issued a $9.00 target price on shares of Savara in a research report on Tuesday, October 1st.

Institutional Trading of Savara

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. CANADA LIFE ASSURANCE Co purchased a new position in shares of Savara during the first quarter valued at approximately $35,000. Choreo LLC bought a new stake in shares of Savara in the 2nd quarter worth $59,000. DRW Securities LLC bought a new stake in shares of Savara in the 2nd quarter worth $62,000. Principal Financial Group Inc. raised its holdings in shares of Savara by 64.4% in the second quarter. Principal Financial Group Inc. now owns 17,795 shares of the company's stock valued at $72,000 after purchasing an additional 6,973 shares during the last quarter. Finally, ProShare Advisors LLC lifted its position in shares of Savara by 9.0% during the first quarter. ProShare Advisors LLC now owns 25,715 shares of the company's stock valued at $128,000 after purchasing an additional 2,114 shares in the last quarter. 87.93% of the stock is owned by institutional investors.

Savara Trading Up 3.0 %

Savara stock traded up $0.11 during trading hours on Friday, reaching $3.76. 1,542,194 shares of the company's stock were exchanged, compared to its average volume of 1,191,352. The firm's 50 day simple moving average is $4.18 and its 200 day simple moving average is $4.36. Savara has a twelve month low of $3.12 and a twelve month high of $5.70. The company has a quick ratio of 11.31, a current ratio of 11.31 and a debt-to-equity ratio of 0.26. The firm has a market capitalization of $519.59 million, a PE ratio of -10.16 and a beta of 0.96.

Savara (NASDAQ:SVRA - Get Free Report) last released its earnings results on Monday, August 12th. The company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.01). Research analysts predict that Savara will post -0.44 earnings per share for the current year.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.